On December 15, TIGERMED was removed from the SZSE 100 Index, ending its six-year tenure in the benchmark. Despite reporting a 20.88% year-on-year increase in net profit for the first three quarters of 2025, its stock price fell 6.7% against the market trend. The company's market capitalization has plummeted from a peak of 170 billion yuan to around 43 billion yuan. Key metrics such as revenue scale, growth rate, and ROE also lag behind the SZSE 100 average.

On the capital front, company executives have continued to reduce their holdings, while institutional investors significantly cut their positions. However, some analysts remain bullish on the stock.

TIGERMED has diversified investments, but recent performance pressure and liquidity concerns have forced it to exit projects to raise capital. Although its net profit has rebounded, the market remains unconvinced. Restoring investor confidence may hinge on the recovery of its core business profitability.